This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hematology				
Bone marrow transplant (BMT)	Cannabinoid CB ₂ receptor (CNR2)	<p><i>In vitro</i> and mouse studies suggest that CNR2 agonists could help improve the effectiveness of BMT. In a mouse model of BMT, hematopoietic stem cells (HSCs) pretreated with a CNR2 agonist had greater engraftment and produced more B, T and myeloid cell lineages than HSCs pretreated with vehicle. Future studies could include investigating whether CNR2 agonists increase the effectiveness of other HSC-based therapies.</p> <p>KN38-7271 (formerly BAY 38-7271), a CNR1 and CNR2 agonist from KeyNeurotek AG and Bayer AG, is in Phase IIa testing to treat traumatic brain injury (TBI) and Phase I testing to treat stroke.</p> <p>Tedalinab (GRC 10693), an oral CNR2 agonist from Glenmark Pharmaceuticals Ltd., is in Phase I testing to treat neuropathic, osteopathic and other types of pain.</p> <p>CR701, a CNR1 and CNR2 agonist from Cara Therapeutics Inc., is in preclinical testing to treat neuropathic pain.</p> <p>SciBX 3(46); doi:10.1038/scibx.2010.1384 Published online Dec. 2, 2010</p>	Patent and licensing status unavailable	<p>Jiang, S. <i>et al. Blood</i>; published online Nov. 9, 2010; doi:10.1182/blood-2010-01-265082</p> <p>Contact: Hava Karsenty Avraham, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass. e-mail: havraham@bidmc.harvard.edu</p>